The company has seen a flat track record when it comes to current year estimate revisions over the past few weeks. The consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
MEIP currently has a Zacks Rank #4 (Sell) while its Earnings ESP is zero.
Some better-ranked stocks in the healthcare sector include Lannett Company, Inc. (LCI), Questcor Pharmaceuticals, Inc. (QCOR) and Shire plc (SHPG). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Be the first to comment